Clinical Trial Update: Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing nasal fentanyl with oral transmucosal fentanyl (Actiq) for cancer breakthrough pain has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Actiq (fentanyl)
• Fentanyl nasal spray (fentanyl)

Snippet

Sponsor: Nycomed | Conditions: Pain | Phase 3 | Status: COMPLETED